Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
GENB · NASDAQ · Pharmaceutical Preparations · No 10-K yet
Generate Biomedicines (GENB) · oqro.io/stocks/GENB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$10.49−1.58 (−13.09%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
No open-market purchase by an insider of Generate Biomedicines is on record in SEC filings since 2006.
Since 2026, Generate Biomedicines insiders reported 0 open-market purchases and 1 sale on Forms 4 and 5.
In the last 90 days, 1 insider of Generate Biomedicines (GENB) reported 1 open-market sale worth $185K in total on SEC Form 4. The largest seller by value was Frances Arnold, with $185K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Generate Biomedicines (GENB) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−17.1% (−$2.16) from Feb 27, 2026 to Nov 16, 2026 · adjusted daily closes
Adjusted close went from $12.65 on Feb 27, 2026 to $10.49 on Nov 16, 2026 (−17.1%). Disclosed in this range: 0 insider trades, 1 pre-arranged insider sale, 0 Congress trades, and 5 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Somerville, MA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$1.35B
Short interest: 9.08M shares sold short (7.0% of shares outstanding), +1.7% vs the previous count, 8.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$4.22M
−56.2% vs the same quarter a year earlier
Free cash flow, last 12 months
−$57M
This quarter −$57M, a year earlier −$48.7M
Net debt
—
Debt —, cash $140M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Generate Biomedicines over the 12 months to Nov 17, 2026: 2 clinical trials.
Insiders of Generate Biomedicines reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $185K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Feb 27, 2026, GENB is down 17.1% and the index fund is up 7.9%: 25 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much GENB moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
2 active phase 3 trials and 0 active phase 2 trials led by this company, mostly in severe asthma. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
7 certified in FY2026 Q3, vs 3 a year earlier. 7 positions in total, median offered wage $135K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.